European Morning Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Morning Report.

Press releases published on September 28, 2026

Sep. 28, 2026

MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China

Indeterminate GlobeNewswire

Sep. 28, 2026

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Indeterminate GlobeNewswire

Sep. 28, 2026

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

Indeterminate GlobeNewswire

Sep. 28, 2026

Lifecore Biomedical to be Acquired by Webster Equity Partners

Indeterminate GlobeNewswire

Sep. 28, 2026

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

Indeterminate GlobeNewswire

Sep. 28, 2026

Fluke Delivers Confidence with New Electrical Testing Bundles to Equip the Next Generation of Electricians

Indeterminate GlobeNewswire

Sep. 28, 2026

Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026

Indeterminate GlobeNewswire

Sep. 28, 2026

Latin Metals Receives C$1.875 Million from Warrant Exercises

Indeterminate GlobeNewswire

Sep. 28, 2026

Samaritan Expands Vigil With Monitor, Research, Report, and Respond Workflow

Indeterminate EIN Presswire

Sep. 28, 2026

ASML reports transactions under its current share buyback program

Indeterminate GlobeNewswire

Sep. 28, 2026

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Indeterminate GlobeNewswire

Sep. 28, 2026

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Indeterminate GlobeNewswire

Sep. 28, 2026

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Indeterminate GlobeNewswire

Sep. 28, 2026

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

Indeterminate GlobeNewswire

Sep. 28, 2026

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Indeterminate GlobeNewswire

Sep. 28, 2026

Quantum Cyber Files Audited and Reviewed Financial Statements and Pro Forma Financial Information for Bridgeport Manufacturing Acquisition

Indeterminate GlobeNewswire

Sep. 28, 2026

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Indeterminate GlobeNewswire

Sep. 28, 2026

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

Indeterminate GlobeNewswire

Sep. 28, 2026

4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program

Indeterminate GlobeNewswire

Sep. 28, 2026

Pasqal Announces an Evolution of Its Collaboration Framework with the French Public Authorities

Indeterminate GlobeNewswire